Tumor doubling time and prognostic assessment of primary lung cancer patients

Usuda, K; Nakada, Taka‐aki; Okaniwa, G; Saito, Yasutoshi; Sagawa, Masano; Sato, Michiko; Kanma, Keiji; Takahashi, Shunji; Endo, Chiaki; Chen, Y; Sakurada, Akira; K, Aikawa; Fujimura, S

doi:10.1016/0169-5002(94)94052-5

Cited by 20 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VDT helps to differentiate between benign and malignant pulmonary nodules (1) and is a key parameter in lung cancer screening. Shorter VDT may reflect greater histological tumor aggressiveness, suggesting that lung cancers with a short VDT are associated with a poor prognosis (10). Traditionally, the absence of lesion growth over a 2-year period was regarded as a benign status.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Volume doubling time of lung cancers detected in a chest radiograph mass screening program: Comparison with CT screening

et al. 2012

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…As for mass screening for lung cancer, chest radiography and sputum cytology were performed until the 1990s (10,17,18). Thereafter, a number of studies involved chest CT screening, which is more sensitive for nodule detection (2-7).…”

Section: Discussionmentioning

confidence: 99%

Volume doubling time of lung cancers detected in a chest radiograph mass screening program: Comparison with CT screening

et al. 2012

View full text Add to dashboard Cite

“…Data on tumour volume doubling time (Td) for human lung tumours are reported by Hasegawa et al (2000), Steel (1977), Usuda et al (1994), Fujimura et al (1979), Filderman et al (1986) and Geddes (1979). The data are summarised in Table 4.…”

Section: Repopulation and Tumour Doubling Timementioning

confidence: 99%

Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy

2003

View full text Add to dashboard Cite

Induction chemotherapy of non-small-cell lung cancer (NSCLC) stage III with gemcitabine and cisplatin for downstaging of the tumour with the aim for further treatment with ionising radiation is one of the treatments for lung cancer patients. The purpose of this study was to investigate the influence of the waiting time for radiotherapy, that is, the interval between induction chemotherapy and radiotherapy, on the rate of tumour growth for patients with NSCLC. Interval times between the end of induction chemotherapy and date of diagnostic CT, planning CT and first day of radiotherapy were determined for 23 patients with NSCLC. Increase in gross tumour volume was measured for 18 patients by measuring the dimensions of the primary tumour and lymph node metastases on the diagnostic CT after induction chemotherapy and on the CT used for radiotherapy planning. For each patient, the volume doubling time was calculated from the time interval between the two CTs and ratio of the gross volumes on planning CT and diagnostic CT. The mean time interval between end of chemotherapy and day of diagnostic CT was 16 days, and till first day of radiotherapy 80.3 (range 29 -141) days. In all, 41% of potentially curable patients became incurable in the waiting period. The ratio of gross tumour volumes of the two CTs ranged from 1.1 to 81.8 and the tumour doubling times ranged from 8.3 to 171 days, with a mean value of 46 days and median value of 29 days. This is far less than the mean doubling time of NSCLC in untreated patients found in the literature. This study shows that in the time interval between the end of induction chemotherapy and the start of radiotherapy rapid tumour progression occurs as a result of accelerated tumour cell proliferation: mean tumour doubling times are much shorter than those in not treated tumours. As a consequence, the gain obtained with induction chemotherapy with regard to volume reduction was lost in the waiting time for radiotherapy. We recommend diminishing the time interval between chemo-and radiotherapy to as short as possible.

show abstract

“…For the WHO measurement the lesion area a is computed as π 4 lw whereas, according to the MS equation [5], the lesion volume v is computed as being equal to π 6 l * w 2 ; in both cases, l is the largest diameter length and w is the length of its largest perpendicular.…”

Section: Methodsmentioning

confidence: 99%

The Lung Image Database Consortium (LIDC)

Reeves¹,

Biancardi²,

Apanasovich³

et al. 2007

Academic Radiology

View full text Add to dashboard Cite

Rationale and Objectives-To investigate the effects of choosing between different metrics in estimating the size of pulmonary nodules as a factor both of nodule characterization and of performance of computer aided detection systems, since the latters are always qualified with respect to a given size range of nodules.Materials and Methods-This study used 265 whole-lung CT scans documented by the Lung Image Database Consortium using their protocol for nodule evaluation. Each inspected lesion was reviewed independently by four experienced radiologists who provided boundary markings for nodules larger than 3 mm. Four size metrics, based on the boundary markings, were considered: a uni-dimensional and two bi-dimensional measures on a single image slice and a volumetric measurement based on all the image slices. The radiologist boundaries were processed and those with four markings were analyzed to characterize the inter-radiologist variation, while those with at least one marking were used to examine the difference between the metrics.Results-The processing of the annotations found 127 nodules marked by all of the four radiologists and an extended set of 518 nodules each having at least one observation with three-dimensional sizes ranging from 2.03 to 29.4 mm (average 7.05 mm, median 5.71 mm). A very high inter-observer variation was observed for all these metrics: 95% of estimated standard deviations were in the following ranges [0. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public AccessAuthor Manuscript Acad Radiol. Author manuscript; available in PMC 2008 December 1. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript the uni-dimensional, and the two bi-dimensional size metrics respectively (in mm). Also a very large difference among the metrics was observed: 0.95 probability-coverage region widths for the volume estimation conditional on uni-dimensional, and the two bi-dimensional size measurements of 10mm were 7.32, 7.72, and 6.29 mm respectively.Conclusions-The selection of data subsets for performance evaluation is highly impacted by the size metric choice. The LIDC plans to include a single size measure for each nodule in its database. This metric is not intended as a gold standard for nodule size; rather, it is intended to facilitate the selection of unique repeatable size limited nodule subsets.

show abstract

Tumor doubling time and prognostic assessment of primary lung cancer patients

Cited by 20 publications

References 0 publications

Volume doubling time of lung cancers detected in a chest radiograph mass screening program: Comparison with CT screening

Volume doubling time of lung cancers detected in a chest radiograph mass screening program: Comparison with CT screening

Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy

The Lung Image Database Consortium (LIDC)

Contact Info

Product

Resources

About